Gene Editing Market Expected to Grow to $22.87 Billion by 2032

Advancements in CRISPR and other gene editing platforms drive market expansion, but skilled workforce shortages pose challenges.

Published on Feb. 9, 2026

Got story updates? Submit your updates here. ›

The global gene editing market was valued at $9.78 billion in 2024 and is projected to reach $22.87 billion by 2032, growing at a CAGR of 12.06%. The market growth is driven by the increasing adoption of precision genetic modification technologies across therapeutic, research, and diagnostic applications, as well as rising demand for personalized medicine and expanding treatment pipelines for genetic disorders.

Why it matters

The gene editing market's rapid expansion reflects the growing importance of precision medicine and the potential of advanced genetic modification tools like CRISPR to treat a wide range of genetic disorders. However, the market faces significant challenges, including skilled workforce shortages and concerns over off-target effects, which could limit broader clinical adoption and commercialization.

The details

The gene editing market is segmented by offering (products and services), technology (CRISPR, TALENs, etc.), application (therapeutic, diagnostic, etc.), and end-user (pharmaceutical/biotech companies, research institutes, etc.). CRISPR technology dominates the market, accounting for 61% of the share in 2025, due to its superior efficiency and cost-effectiveness compared to alternative genome editing tools. The therapeutic segment is expected to see the fastest growth, driven by the increasing prevalence of genetic disorders and the effectiveness of gene editing therapies. Pharmaceutical and biotech companies are the largest end-users, leveraging gene editing products for therapeutic application development.

  • The global gene editing market was valued at $9.78 billion in 2024.
  • The market is projected to reach $10.31 billion in 2025 and $22.87 billion by 2032.
  • Vertex Pharmaceuticals received authorization from Saudi Arabia's Food and Drug Authority for its CRISPR/Cas9 gene-edited therapy in January 2024.
  • The Children's Hospital of Philadelphia and Penn Medicine successfully treated a child with severe carbamoyl phosphate synthetase 1 deficiency using customized CRISPR gene editing therapy in May 2025.
  • EditCo Bio launched its XDel Knockout Cells, a CRISPR gene editing product, in January 2025.

The players

Thermo Fisher Scientific Inc.

A leading provider of gene editing products and services, including CRISPR tools and reagents.

Agilent Technologies Inc.

A technology company that acquired BIOVECTRA in 2024 to expand its CDMO capabilities in oligonucleotides and CRISPR therapeutics.

GenScript

A prominent player in the gene editing market, offering a range of CRISPR and other genome editing products and services.

SOHM Inc.

A company that received FDA commentary in November 2025 on the regulatory pathway evolution for genome-editing technologies.

Vertex Pharmaceuticals

A pharmaceutical company that received authorization from Saudi Arabia's Food and Drug Authority for its CRISPR/Cas9 gene-edited therapy in January 2024.

Got photos? Submit your photos here. ›

What’s next

The U.S. Government Accountability Office reported in March 2023 concerning shortages in current and projected laboratory and biomanufacturing technicians supporting regenerative medicine and advanced therapy development, which could impact the gene editing market's growth trajectory.

The takeaway

The gene editing market's rapid expansion highlights the transformative potential of precision genetic modification technologies, particularly CRISPR, in addressing a wide range of genetic disorders. However, the market faces significant challenges, including skilled workforce shortages and concerns over off-target effects, which could slow the broader clinical adoption and commercialization of these innovative therapies.